These findings suggest that the baseline level of TOPBP1 in cells may serve as an indicator of sensitivity to combinatorial olaparib and AZD6738 treatment in PDAC cell lines and primary PDAC tumor cells. Here, TOPBP1 is linked to neoplasm.